Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) is running for the top in the market this morning, and for good reason. The company announced positive data from a Phase 2 clinical trial assessing a cancer therapy. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
SPPI Rockets On Positive Data
In the press release issued early this morning, Spectrum Pharmaceuticals announced that it has met its primary endpoint in a Phase 2 clinical trial. The trial, known as ZENITH20, was designed to evaluate poziotinib in previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.